Onconova Therapeutics, Inc. (NASDAQ:ONTX) – Investment analysts at Dawson James issued their Q2 2017 earnings per share estimates for Onconova Therapeutics in a research report issued on Tuesday. Dawson James analyst R. Wasserman expects that the biopharmaceutical company will post earnings per share of ($0.72) for the quarter. Dawson James currently has a “Buy” rating on the stock. Dawson James also issued estimates for Onconova Therapeutics’ Q3 2017 earnings at ($0.73) EPS, Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($3.30) EPS and FY2018 earnings at ($1.67) EPS.
Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.27. Onconova Therapeutics had a negative return on equity of 574.49% and a negative net margin of 485.01%. The business had revenue of $0.21 million during the quarter. COPYRIGHT VIOLATION NOTICE: “Equities Analysts Set Expectations for Onconova Therapeutics, Inc.’s Q2 2017 Earnings (ONTX)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://weekherald.com/2017/08/08/equities-analysts-set-expectations-for-onconova-therapeutics-inc-s-q2-2017-earnings-ontx-updated.html.
Several other analysts have also issued reports on ONTX. Maxim Group restated a “buy” rating and set a $6.00 price target on shares of Onconova Therapeutics in a research report on Tuesday, April 4th. Laidlaw started coverage on shares of Onconova Therapeutics in a report on Thursday, April 27th. They set a “buy” rating and a $10.00 target price for the company.
Onconova Therapeutics (NASDAQ:ONTX) opened at 1.95 on Friday. The stock has a 50 day moving average price of $2.05 and a 200 day moving average price of $2.43. The company’s market capitalization is $18.50 million. Onconova Therapeutics has a 52-week low of $1.78 and a 52-week high of $4.12.
A hedge fund recently raised its stake in Onconova Therapeutics stock. Renaissance Technologies LLC boosted its position in Onconova Therapeutics, Inc. (NASDAQ:ONTX) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 122,700 shares of the biopharmaceutical company’s stock after buying an additional 26,200 shares during the period. Renaissance Technologies LLC owned approximately 1.82% of Onconova Therapeutics worth $279,000 as of its most recent SEC filing. Institutional investors own 15.44% of the company’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.